Badania kliniczne w Polsce, których sponsorem jest Takeda Development Center Americas Inc.. Sponsor odpowiada za zaplanowanie, prowadzenie i finansowanie badania.
25 badań w Polsce: 25 rekrutuje. Ośrodki w 33 miastach.
Sponsor niezweryfikowany
Sponsor niezweryfikowany. Nazwa sponsora i lista badań pochodzą z publicznych rejestrów badań klinicznych (CTIS, ClinicalTrials.gov). Sponsor nie potwierdził tych danych z nami.
Wpisz słowo, żeby przeszukać wszystkie 25 badań.
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood…
+21Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
+20A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
+1A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
+9A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
+21A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
+12A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
+13A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
+3A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
+12A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
+12A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
+4A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
+18A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis
+1A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
+8A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
+17A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
+18Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
+6A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
+9A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
+10Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
+11A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
+10A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
+8A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
+10Według daty pojawienia się badania w rejestrze (CTIS lub ClinicalTrials.gov).
Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 3 października 2026.